Recently, our holding subsidiary, Beijing Huonland Pharmaceutical Co., Ltd. (hereinafter referred to as “Huonland”), received a notice issued by the Beijing Municipal Administration for Drug Supervision. Medicine GMP Notification of Compliance Inspection (Beijing Drug Administration – Pharmaceutical) GMP[2025]020005 ). The company’s newly built single-dose eye-drop production line ( 04 Line) Passed smoothly GMP The compliance inspection signifies that this production line is now fully qualified and capable of commercial production, representing another authoritative recognition of Huirenland’s quality management system and production capacity. It will also inject strong momentum into the company’s performance growth.

Eye drops 04 The production line is a fully automated, high-standard, and intelligent production line independently invested in and built by Huonland. The key equipment on the new production line all comes from top domestic suppliers such as Chutian Technology and Dongfulong, and is equipped with fully automatic aseptic systems. BFS The integrated blow-fill-seal system, high-precision online leak detection equipment, and packaging system enable fully automated operation—from liquid preparation and filling to packaging. The production line is also equipped with... SCADA The system enables precise control of various parameters throughout the production process. While reducing errors that may arise from manual operations, it also ensures the integrity and traceability of production data. By integrating the “full lifecycle” quality management concept throughout the entire process, the system significantly enhances both production efficiency and the reliability of product quality.

The single-dose production line has an annual production capacity of: 1.5 100 million units—increasing the annual production capacity of single-dose eye drops to... 2.2 100 million units, growth 214% Breaking through capacity bottlenecks and ensuring product quality will provide strong support for the company’s commercialization strategy in the ophthalmology field, helping the company actively expand its market and offer more high-quality, safe, and effective eye-drop products—thus becoming a new engine driving the company’s sustained performance growth.

NORTHLAND is dedicated to the research, development, production, and commercialization of gene therapy drugs, recombinant protein drugs, and ophthalmic products. As an important component of NORTHLAND’s product pipeline, the company’s established comprehensive quality management system, production management system, and marketing management system have laid a solid foundation for its pharmaceutical management operations, provided a valuable reference for the commercialization of biologics, and offered financial support for the high-investment, long-cycle research and development of innovative biological drugs. NORTHLAND’s globally first human naked plasmid gene therapy drug—Donaperminogene Seltoplasmid Ingection—intended for the treatment of severe lower-limb ischemic disease has completed Phase III clinical trials and has submitted a New Drug Application. The company is currently actively preparing supplementary documentation to respond to regulatory feedback. The company remains committed to being guided by clinical needs and to developing “biological drugs” + The “dual-engine” model for ophthalmic medications continues to develop high-quality pharmaceutical products in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic conditions, striving to achieve the company’s own high-quality development and contributing to the advancement of the national pharmaceutical industry.